With the opioid crisis gripping the United States, many doctors have been looking at alternate treatments to help patients with long-term chronic pain. A new study shows that the venom from a scorpion sting could provide a solution.

Former U.S. National Football League (NFL) athletes who bulked up before and during their professional careers have an increased risk of heart disease and other health problems compared with other players, researchers say.

A late-stage study for fasinumab conducted by Regeneron Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. hit the mark in assessing patients with chronic pain from osteoarthritis of the knee or hip.

DyAnsys Inc. announced that the U.S. Food and Drug Administration cleared the company’s auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.

During its second-quarter 2017 financial reporting, Egalet Corporation also announced it plans to cut the company’s non-sales staff by almost 40 percent.

Shares of pain-relief company Cara Therapeutics were up more than 16 percent after the company grabbed the Breakthrough Therapy Designation for its chronic kidney disease treatment CR845.

Pfizer Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).

Zoetis Inc. and Nexvet Biopharma plc announced an agreement. Zoetis, through a wholly owned subsidiary (Zoetis Bidco), will purchase Nexvet, an innovator in monoclonal antibody therapies for companion animals, for a purchase price of US$6.72 per share, representing an aggregate equity valuation of approximately $85 million.

Regular use of pain relievers over many years may increase the risk of hearing loss, a recent study suggests.

Indianapolis-based Eli Lilly and Company is on a roll, announcing that between 2014 and 2023, it may launch 20 new products.